Pegfilgrastim Biosimilars Global Market Report 2024

The pegfilgrastim biosimilars market size has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.75 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The expansion observed in the historical period can be ascribed to factors such as the rise in cancer prevalence, governmental initiatives, augmented healthcare expenditure, an upswing in biopharmaceutical research and development spending, the cost-effectiveness of biosimilars, and widespread adoption of biosimilar drugs.

The pegfilgrastim biosimilars market size is expected to see strong growth in the next few years. It will grow to $2.32 billion in 2028 at a compound annual growth rate (CAGR) of 7.4%. The anticipated growth in the forecast period can be attributed to factors such as the increasing prevalence of cancer, a growing aging population, a rising number of approvals, and the presence of targets and incentives. Noteworthy trends in the forecast period encompass leveraging less stringent regulations for the development of novel and enhanced biosimilars, substantial investments in research and development endeavors to create effective and innovative biologics, a strategic emphasis on establishing partnerships with prominent players to broaden research and development activities for new drug developments, and an increased focus on merger and acquisition growth strategies to expand the customer base and geographic markets. Additionally, there is a heightened focus on the production of biosimilars for the treatment of neutropenia to enhance revenues and product offerings.

Government initiatives aimed at promoting the development of biosimilars are anticipated to be a driving force behind the pegfilgrastim biosimilars market. Governments on a global scale are prioritizing biosimilar development due to its cost-effectiveness. Initiatives such as the Biosimilar Action Plan launched by the US Food and Drug Administration (FDA) to expand treatment options and the commitment of the Australian government to the Biosimilar Awareness Initiative through a $5 million grant to support biosimilar education and activities highlight the concerted efforts to enhance awareness and production of biosimilars. These endeavors contribute to the overall growth of the pegfilgrastim biosimilars market.

The increasing prevalence of cancer is expected to be a significant factor propelling the growth of the pegfilgrastim biosimilars market. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, has seen a rise in new cases. Pegfilgrastim biosimilars play a crucial role in reducing the risk of infection in cancer patients undergoing chemotherapy by stimulating white blood cell production. For example, in 2021, The American Cancer Society reported an increase in new cancer cases in the USA from 1.8 million in 2020 to 1.9 million in 2021, with a slight rise in cancer-related deaths from 606,520 in 2020 to 608,570 in 2021. Consequently, the growing incidence of cancer is a key driver for the pegfilgrastim biosimilars market.


Companies operating in the pegfilgrastim biosimilar market are enhancing their product innovation through strategic collaborations. To thrive in the increasingly competitive market, these companies are not only developing innovative products but also leveraging partnerships to share skills and expertise. While collaborations with academic and research institutions have been a common practice, this trend has gained momentum in recent years. For example, in May 2023, Amneal Pharmaceuticals, a US-based generics and specialty pharmaceutical company, joined forces with Kashiv Biosciences, a US-based integrated biosciences company, to collaboratively develop and introduce Fylnetra (pegfilgrastim-pbbk), a biosimilar pegfilgrastim. Fylnetra is a preservative-free, clear solution provided in a 6 mg/0.6 mL single-dose prefilled syringe, aiming to reduce infection risks, specifically febrile neutropenia, in patients with non-myeloid cancers undergoing certain myelosuppressive anti-cancer treatments.

Major companies in the pegfilgrastim biosimilars market are introducing high-quality products such as Stimufend to offer improved alternatives. Stimufend, launched by Fresenius Kabi, a Germany-based healthcare company, in February 2023, is a therapeutic drug designed to assist cancer patients in addressing neutropenia. Available as a 6 mg/0.6 mL solution in a single-use pre-filled syringe with a built-in needle guard, Stimufend marks the company's entry into the U.S. biosimilars market for cancer care, providing healthcare professionals with a high-quality treatment alternative.

In February 2022, Biocon Biologics Ltd., an India-based fully integrated biopharmaceutical company, completed the acquisition of Viatris' biosimilar business for $3.34 billion. This strategic move enables Biocon Biologics to direct-market more of its existing and upcoming biosimilars. As part of the acquisition, Viatris, a US-based pharmaceutical and healthcare corporation, is expected to provide commercial and other transition services to ensure a smooth transition and maintain customer service for an anticipated two-year term.

Major companies operating in the pegfilgrastim biosimilars market report are Coherus BioSciences, Sandoz, Biocon/Mylan, Intas Biopharmaceuticals Ltd., Mundipharma GmbH, Dr. Reddy’s Laboratories, Pfizer Inc., Emcure Pharmaceuticals, USV Private Limited, Apotex Pty Ltd., Kyowa Kirin Co. Ltd., Qilu Pharmaceutical, Gennova Biopharmaceuticals Limited, Lupin Limited, Coherus Biosciences Inc., Fresenius Kabi, Napp Pharmaceuticals, Boicon, Amega Biotech.

North America was the largest region in the pegfilgrastim biosimilars market in 2023. The Middle East is expected to be the fastest growing region in the global pegfilgrastim biosimilars market share during the forecast period. The regions covered in the pegfilgrastim biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pegfilgrastim biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

The diverse applications of pegfilgrastim biosimilars include their use in chemotherapy treatment, transplantation, and other medical scenarios. Chemotherapy is a cancer treatment method that involves the administration of one or more anti-cancer medications following a specified protocol. These biosimilars are made available through various distribution channels, including hospital pharmacies, retail pharmacies, and mail-order pharmacies.

The pegfilgrastim biosimilars market research report is one of a series of new reports that provides pegfilgrastim biosimilars market statistics, including pegfilgrastim biosimilars industry global market size, regional shares, competitors with a pegfilgrastim biosimilars market share, detailed pegfilgrastim biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the pegfilgrastim biosimilars industry. This pegfilgrastim biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pegfilgrastim biosimilars market consists of sales of fulphila, pelgraz, pelmeg, udenyca, ziextenzo, grasustek, fylnetra, and stimufend. Values in this market are 'factory gate values,' that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.